MS200527-0018 A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Examining the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

August 15, 2018
https://clinicaltrials.gov/ct2/show/NCT02975336
Rheumatology
Principal Investigator: Kathleen M Maksimowicz-Mckinnon, DO
Lupus, Systemic Lupus Erythamatosis
Accepting Participants